CAR T Cells in Human Cancers
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 25 November 2025 | Viewed by 36
Special Issue Editors
Interests: CAR T cells; cancer immunotherapy; immune checkpoint inhibitors; CAR T cell engineering; tumor microenvironment
Interests: human cancers; radiation therapy; cancer biology; breast cancer; lipid metabolism
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapies have transformed the treatment landscape, offering new hope for patients with cancers once considered difficult to treat. Among these therapies, CAR T cells have shown remarkable success in hematologic cancers and are being explored for their potential in solid tumors. However, challenges remain in improving their efficacy, persistence, and safety. Beyond CAR T cells, other immune-based therapies, including immune checkpoint inhibitors, TCR-T cells, and NK cell-based therapies, are also gaining attention for their ability to harness the immune system to target cancer.
We are pleased to announce a Special Issue of Cells, titled "CAR T Cells in Human Cancers". This Special Issue invites researchers to submit original research and reviews exploring innovations in cancer immunotherapy. We encourage contributions on CAR T cells, as well as other engineered immune cell therapies, focusing on CAR T design improvements, mechanisms of action, tumor microenvironment modulation, combination therapies, immune checkpoint modulation, and novel strategies to improve treatment outcomes in hematologic and solid cancers. This Special Issue aims to provide a comprehensive overview of the diverse landscape of cancer immunotherapies and their potential to reshape cancer treatment.
Dr. Tabish H. Khan
Dr. Naoshad Muhammad
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T cells
- engineered immune cell therapies
- CAR T cell engineering
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
